These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

157 related items for PubMed ID: 33413291

  • 1. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate administered as an inhaled fixed-dose combination in Japanese and Caucasian healthy subjects.
    Inoue S, Vaidya S, Tillmann HC, Sakita Y, Machineni S, Heudi O, Furihata K.
    BMC Pulm Med; 2021 Jan 07; 21(1):18. PubMed ID: 33413291
    [Abstract] [Full Text] [Related]

  • 2. Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once-daily inhalation as a combination in healthy subjects.
    Vaidya S, Jauernig J, Ethell B, Abdallah N, Machineni S, Drollmann A, Heudi O, Last S, Hahn M, Radhakrishnan R, Ignatenko S, Tillmann HC.
    Pulm Pharmacol Ther; 2020 Oct 07; 64():101964. PubMed ID: 33035700
    [Abstract] [Full Text] [Related]

  • 3. Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler® Device in Patients with Asthma.
    Bartels C, Jain M, Yu J, Tillmann HC, Vaidya S.
    Eur J Drug Metab Pharmacokinet; 2021 Jul 07; 46(4):487-504. PubMed ID: 34024035
    [Abstract] [Full Text] [Related]

  • 4. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
    Kerstjens HAM, Maspero J, Chapman KR, van Zyl-Smit RN, Hosoe M, Tanase AM, Lavecchia C, Pethe A, Shu X, D'Andrea P, IRIDIUM trial investigators.
    Lancet Respir Med; 2020 Oct 07; 8(10):1000-1012. PubMed ID: 32653074
    [Abstract] [Full Text] [Related]

  • 5. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON).
    Gessner C, Kornmann O, Maspero J, van Zyl-Smit R, Krüll M, Salina A, Gupta P, Bostel S, Fucile S, Conde LG, Pfister P.
    Respir Med; 2020 Oct 07; 170():106021. PubMed ID: 32843164
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetics of QMF149 in Japanese versus Caucasian subjects: an open-label, randomized phase I study.
    Shimada S, Vaidya S, Khindri S, Tashiro N, Cheng Y, Hara H, Majumdar T, Woessner R, Furihata K, Kobayashi K.
    Int J Clin Pharmacol Ther; 2015 May 07; 53(5):398-407. PubMed ID: 25740265
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Letter to the editor: indacaterol/glycopyrronium/mometasone furoate compared with salmeterol/fluticasone propionate in patients with asthma: a randomized controlled cross-over study.
    Watz H, Hohlfeld JM, Singh D, Beier J, Diamant Z, Liu J, Hua S, Abd-Elaziz K, Pinot P, Jones I, Tillmann HC.
    Respir Res; 2020 Apr 15; 21(1):87. PubMed ID: 32295593
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma.
    Brittain D, D'Andrea P, Gruen E, Hosoe M, Jain D, Jauernig J, Pethe A, Scosyrev E, Tanase AM, Tillmann HC.
    Adv Ther; 2022 Jun 15; 39(6):2365-2378. PubMed ID: 35072888
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Long-term safety of once-daily indacaterol acetate/glycopyrronium bromide/mometasone furoate high-dose, and indacaterol acetate/mometasone furoate high-dose, in Japanese patients with inadequately controlled asthma: Results from two open-label, 52-week studies.
    Sagara H, D'Andrea P, Tanase AM, Pethe A, Tanaka Y, Matsuo K, Hosoe M, Nakamura Y.
    J Asthma; 2023 Feb 15; 60(2):403-411. PubMed ID: 35348408
    [Abstract] [Full Text] [Related]

  • 14. Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study.
    van Zyl-Smit RN, Krüll M, Gessner C, Gon Y, Noga O, Richard A, de Los Reyes A, Shu X, Pethe A, Tanase AM, D'Andrea P, PALLADIUM trial investigators.
    Lancet Respir Med; 2020 Oct 15; 8(10):987-999. PubMed ID: 32653075
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone/indacaterol/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post hoc analysis from the IRIDIUM study.
    Van Zyl-Smit RN, Kerstjens HA, Maspero JF, Kostikas K, Hosoe M, Tanase AM, D'Andrea P, Mezzi K, Brittain D, Lawrence D, Chapman KR.
    Respir Med; 2023 May 15; 211():107172. PubMed ID: 36906187
    [Abstract] [Full Text] [Related]

  • 16. Efficacy of one time per day, single-inhaler indacaterol/glycopyrronium/mometasone in patients with inadequately controlled asthma: post hoc analysis of IRIDIUM study in Asian population.
    Sagara H, Barbier N, Ishii T, Yoshisue H, Nikolaev I, Hosoe M, Gon Y.
    BMJ Open Respir Res; 2021 Mar 15; 8(1):. PubMed ID: 33737310
    [Abstract] [Full Text] [Related]

  • 17. Cost-Utility Analysis of Fixed-Dose Combination of Indacaterol Acetate Glycopyrronium Bromide and Mometasone Furoate as a Maintenance Treatment in Adult Patients with Asthma Not Adequately Controlled with a Maintenance Combination of a Long-Acting Beta-Agonist and a High Dose of an Inhaled Corticosteroid Who Experienced One or More Asthma Exacerbations in the Previous Year.
    Mangia PP, Gallo O, Ritrovato D, Pradelli L.
    Clin Drug Investig; 2021 Sep 15; 41(9):785-794. PubMed ID: 34333742
    [Abstract] [Full Text] [Related]

  • 18. Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients.
    Miller D, Vaidya S, Jauernig J, Ethell B, Wagner K, Radhakrishnan R, Tillmann HC.
    Respir Res; 2020 Sep 23; 21(1):248. PubMed ID: 32967685
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of inhaled once-daily low-dose indacaterol acetate/mometasone furoate in patients with inadequately controlled asthma: Phase III randomised QUARTZ study findings.
    Kornmann O, Mucsi J, Kolosa N, Bandelli L, Sen B, Satlin LC, D'Andrea P.
    Respir Med; 2020 Jan 23; 161():105809. PubMed ID: 32056721
    [Abstract] [Full Text] [Related]

  • 20. A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in patients with asthma.
    Buhl R, Tanase AM, Hosoe M, Cao W, Demin I, Bartels C, Jauernig J, Ziegler D, Patalano F, Hederer B, Kanniess F, Tillmann HC.
    Pulm Pharmacol Ther; 2020 Jun 23; 62():101919. PubMed ID: 32387408
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.